Tazomeline

Tazomeline

Tazomeline is a pharmacological agent that was developed by Eli Lilly and Company. It is classified as a M1 muscarinic receptor agonist. Tazomeline was primarily investigated for its potential use in the treatment of Alzheimer's disease and schizophrenia, but development was discontinued in the late 1990s.

History

Tazomeline was first synthesized by researchers at Eli Lilly and Company in the early 1990s. The compound was developed as part of a larger effort to discover new treatments for neurodegenerative diseases and psychiatric disorders. Initial studies showed that Tazomeline had a high affinity for the M1 muscarinic receptor, which is involved in many important cognitive functions.

Pharmacology

Tazomeline is a selective agonist for the M1 muscarinic receptor. This receptor is one of five subtypes of muscarinic receptors (M1-M5) and is primarily found in the brain and gastric glands. Activation of the M1 receptor by Tazomeline can enhance cognitive function and potentially alleviate symptoms of diseases like Alzheimer's and schizophrenia.

Clinical Trials

Several clinical trials were conducted to assess the safety and efficacy of Tazomeline in the 1990s. These trials focused on patients with Alzheimer's disease and schizophrenia. However, the results were mixed, and development of Tazomeline was ultimately discontinued.

Discontinuation

The development of Tazomeline was discontinued in the late 1990s. The reasons for this decision are not publicly available, but it is likely that the compound did not meet the necessary safety and efficacy standards in clinical trials.

See Also

• Muscarinic acetylcholine receptor
• Alzheimer's disease
• Schizophrenia
• Eli Lilly and Company

‎

‎

‎